Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Hold tight folks
View:
Post by CaseyL on Feb 13, 2024 8:39am

Hold tight folks

Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. “I am especially pleased to note that this is the third indication from the GOBLET study in a row to meet its success criteria and the fourth indication combining pelareorep and atezolizumab to present positive data, further validating the potential clinical benefit of this combination and opening the door to another potential registrational pathway for pelareorep. Furthermore, we’ve seen another complete response in an indication where checkpoint inhibitor therapy alone has had limited success historically, which bodes well for the potential of pelareorep to work synergistically with multiple immunotherapies in multiple tumor types.”
Comment by itntdf on Feb 13, 2024 10:48am
any link for this "news"?
Comment by canadafan on Feb 13, 2024 2:00pm
That news, was a while ago. does not make it stale or wrong. i do agree , they need something new to re kindle the excitement. any news on Notable? mysterious person. Lots of posts, then gone!
Comment by fasttrack5 on Feb 13, 2024 2:48pm
Registrational Study TBD HR+/HER2- mBC Phase 1 Phase 2 Phase 3 In  In their pipeline waiting for phase 3
Comment by fasttrack5 on Feb 13, 2024 2:51pm
Just one of four with Roche as collaborator 
Comment by 13X2413 on Feb 13, 2024 7:44pm
I haven't monitored the progress bars on the pipeline section of the website. Has anybody noticed any movement in those?
Comment by fasttrack5 on Feb 14, 2024 12:51am
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiilOuVkaqEAxXPDDQIHYWZB2cQjBB6BAgTEAE&url=https%3A%2F%2Foncolyticsbiotech.com%2Fpipeline%2F&usg=AOvVaw0chmmccIr8fOAeNEY3W1nM&opi=89978449
Comment by fasttrack5 on Feb 14, 2024 12:57am
OOPs that last message is not allowed from  Linked in.
Comment by itntdf on Feb 13, 2024 11:02am
yeah, my knuckles are white.  this is from a news release that's over 3 months old.
Comment by Azzak34 on Feb 13, 2024 11:08am
You're right, that good news is no longer valid and has expired. Clinical trial results are like milk and 3 months is way out of date.  Silly goose. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities